De-risk Aseptic Fill-Finish Manufacturing
Maintain product stability and purity in your formulation and aseptic fill-finish manufacturing. Avantor’s integrated, scalable solutions help reduce risk, uphold regulatory compliance, and assure product efficacy and safety.
Supporting your Formulation Strategy
Across modalities, fill-finish is the final step before a drug reaches the patient, so there is no room for error. Avantor’s solutions for aseptic fill-finish manufacturing are designed to maintain product stability, reduce contamination risk and meet stringent global regulatory standards. With deep experience across modalities and expertise in tailoring solutions to your process and facility environment, we help you avoid delays bringing safe, effective therapies to patients.
Monoclonal antibody (mAb) therapies demand high stability and viscosity control during formulation. Avantor provides excipients, buffers, and surfactants, as well as flexible fluid handling options designed to preserve protein structure, mitigate aggregation, and maintain sterility throughout the fill-finish process.
Preserving viral vector viability during aseptic fill-finish is essential for gene therapies. Avantor delivers high-performance excipients, cryoprotectants, designed to maintain vector titers and fluid management technologies that reduce mechanical stress in GMP production.
Related Products
Ensure sterile filtration integrity with Avantor configurable PUPSIT assemblies, designed to streamline aseptic fill-finish manufacturing operations and meet global regulatory compliance.
Support formulation stability with high-purity buffers, sugars, and surfactants from Avantor. Our cGMP and multi-compential compliant portfolio helps maintain pH, control viscosity, and protect biological integrity in aseptic processes.
Simplify complex fluid paths with fill-finish assemblies built on an open-architecture design. Benefit from reduced contamination risk, as well as a flexible and agile design.
